Person:
EKER, SALİH SAYGIN

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

EKER

First Name

SALİH SAYGIN

Name

Filters

20152
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Relationship between antidepressant prescription rates and features of schizophrenic patients and its outcome in schizophrenia treatment
    (Türk Noropsikiyatri Derneği, 2015-03-01) Hancı, Nurcan; Eker, Özlem Çetin; Miraloğlu, Özlem; Uslu, Meral Argün; Özkaya, Güven; Eker, Salih Saygın; Hancı, Nurcan; Eker, Özlem Çetin; Miraloğlu, Özlem; Uslu, Meral Argün; ÖZKAYA, GÜVEN; EKER, SALİH SAYGIN; Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Anabilim Dalı.; 0000-0003-0297-846X; 0000-0002-4345-0517; A-4421-2016; Q-9477-2019; CTO-3128-2022; CNL-3453-2022; FNP-5202-2022; JTT-6561-2023
    Introduction: Comorbid depression in schizophrenia is associated with poor outcome, increased risk of relapse and a high rate of suicide. Identification of depressive symptoms and their appropriate treatment is crucial for depressed schizophrenic patients. The aim of this study is to investigate the rates of antidepressant prescription and their outcomes.Methods: The records of the schizophrenic outpatients, who were consulted at Psychosis Unit of Psychiatry Department between January 2007 and September 2012, were evaluated retrospectively. Enrolled schizophrenic patients' antidepressant medications were at their minimal effective doses and effective duration.Results: The present study demonstrates that 39 of the 101 patients during their follow-ups were prescribed antidepressants. The mean follow-up period was 6.3 (+/- 4.2) years; the mean age at onset was 22 (+/- 6.5) years; the mean duration of illness was 14.7 (+7.3) years and the mean number of psychotic exacerbation was 5 (+/- 3.7). The most prescribed antidepressants were; sertraline (36.9%), venlefaxine (23.8%) and essitalopram (20.2%). SSRI's were prescribed 57 (73.1%), where as SNRI's 21 times (26.9%). There was no significant difference between SSRI (78.6%) and SNRI (21.4%) treatments in terms of psychotic exacerbation under antidepressant medication. Full remission of depressive symptoms was achieved in 21 patients (53.8%). Remission rates were significantly higher (p<0.01) in SNRI treated depressed schizophrenic patients (85.7%) compared to SSRI treated patients (50.9%). In 8 of the 39 patients (20.5%) antidepressant treatment was terminated due to side effects.Conclusion: This study demonstrates that SSRI's were more often prescribed compared to other classes of antidepressants in emerging depressive symptoms in schizophrenic patients despite full remission with SNRI's is more common. There was no significant difference between SSRI and SNRI treatment in terms of psychotic exacerbation.
  • No Thumbnail Available
    Publication
    The efficacy of flupenthixol decanoate in bipolar disorder patients who have no sufficient remission with existing treatments
    (Cumhuriyet Üniversitesi Tıp Fak Psikiyatri Anabilim Dalı, 2015-10-01) Eker, Salih Saygın; Akkaya, Cengiz; Pirinçci, Erdal; Cangür, Şengül; Kırlı, Selçuk; EKER, SALİH SAYGIN; AKKAYA, CENGİZ; Pirinçci, Erdal; KIRLI, SELÇUK; Uludağ Üniversitesi/Tıp Fakültesi/Ruh Sağlığı ve Hastalıkları Anabilim Dalı; Q-9477-2019; EKJ-8427-2022; FVU-0359-2022; CZU-1387-2022
    Objective: It is aimed to evaluate the prophylactic effect of flupenthixol decanoate in remitted BD patients. Methods: Remitted patients with bipolar disorder (BD), who had at least one mood episode each year in the last five years in spite of adequate pharmacotherapy, were included. Flupenthixol decanoate 20 mg/ml was administered in every two weeks. Hamilton Depression Rating Scale (HDRS), Young Mania Rating Scale (YMRS), Bipolar Disorder Functioning Questionnaire (BDFQ), General Assessment of Functionality (GAF) and Side Effect Rating Scale (UKU) were applied. Patients were followed up for 12 months. Results: Eight patients with a mean age of 34.7 +/- 7.5 were enrolled to the study. None of the patients were under monotherapy before the study enrollment. Three (37.5%) of the three patients were dropped out. The data of remaining 5 patients' were evaluated. At the end of the study mean number of mood episodes declined to 0.2 +/- 0.4 per year indicating a statistical significance and the mean score of BDFQ declined to 119.6 +/- 2.7. Conclusions: Flupenthixol decanoate significantly improved functionality and decreased the number of mood episodes allowing an alternative treatment even in remitted BD patients.